home / stock / sngx / sngx articles
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded up 0.85% to 35,729...
The FDA has cleared Soligenix Inc's (NASDAQ: SNGX) Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX94...
Gainers Impel Pharmaceuticals Inc. (NASDAQ: IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday. AGBA Group Holding Limit...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's ( Nasdaq:SNGX ) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte...